Tuccinardi Tiziano, Martinelli Adriano, Nuti Elisa, Carelli Paolo, Balzano Federica, Uccello-Barretta Gloria, Murphy Gillian, Rossello Armando
Dipartimento di Scienze Farmaceutiche, Università di Pisa, via Bonanno 6, 56126 Pisa, Italy.
Bioorg Med Chem. 2006 Jun 15;14(12):4260-76. doi: 10.1016/j.bmc.2006.01.056. Epub 2006 Feb 17.
Ab initio calculations (B3LYP/Lanl2DZ level of theory) were performed in this study to determine all the structural and catalytic zinc parameters required in order to study MMPs and their complexes with hydroxamate inhibitors by means of the AMBER force field. The parameters thus obtained were used in order to study the docking of some known MMPi (Batimastat, CGS 27023A and Prinomastat) and our previously described inhibitor a which had shown an inhibitory activity for MMP-1, and -2, with the aim of explaining the different selectivity. On this basis the two enantiomers (R)-b and (S)-b were designed and synthesized, as more potent MMP-2 inhibitors than our previously described inhibitor a. Between these two enantiomers the eutomer (R)-b proved to be 24.7 times and 15.3 times more potent than CGS 27023A and the parent compound a on MMP-2, maintaining a higher index of MMP-2/MMP-1 selectivity compared with CGS 27023A and the more potent inhibitor Prinomastat. The hydroxamate (R)-b can be considered as a progenitor of a new class of biphenylsulfonamido-based inhibitors that differ from compound a in the presence of an alkyl side chain on the C alpha atom, and show different potency and selectivity profiles on the two MMPs considered.
本研究进行了从头算计算(理论水平为B3LYP/Lanl2DZ),以确定通过AMBER力场研究基质金属蛋白酶(MMPs)及其与异羟肟酸酯抑制剂的复合物所需的所有结构和催化锌参数。所获得的参数用于研究一些已知的基质金属蛋白酶抑制剂(batimastat、CGS 27023A和prinomastat)以及我们之前描述的对MMP-1和-2具有抑制活性的抑制剂a的对接情况,目的是解释不同的选择性。在此基础上,设计并合成了两种对映体(R)-b和(S)-b,它们作为比我们之前描述的抑制剂a更有效的MMP-2抑制剂。在这两种对映体中,优映体(R)-b在MMP-2上的效力分别比CGS 27023A和母体化合物a高24.7倍和15.3倍,与CGS 27023A和更有效的抑制剂prinomastat相比,保持了更高的MMP-2/MMP-1选择性指数。异羟肟酸酯(R)-b可被视为一类新型联苯磺酰胺基抑制剂的前身,它与化合物a的不同之处在于α碳原子上存在烷基侧链,并且在所考虑的两种MMP上显示出不同的效力和选择性特征。